Specialty pharmaceutical company iX Biopharma Ltd. (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that its Phase 2a and 2b clinical trials for its lead product, Wafermine™, have proven successful. The results confirmed a rapid onset of pain relief, along with good tolerability. WafermineTM, is one of three iX Biopharma products currently under development and the world’s first oral- sublingual analgesic employing ketamine as its active compound.
